









Markets
/
Stocks
/
nasdaq-nmtc
/

NeuroOne Medical Technologies Corp

NMTC

0.732USD

+0.009+1.25%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

36.46MMarket Cap

LossP/E TTM



NeuroOne Medical Technologies Corp

0.732

+0.009+1.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NeuroOne Medical Technologies Corp

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NeuroOne Medical Technologies Corp's Score

Industry at a Glance

Industry Ranking

114 / 210

Overall Ranking

254 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

2.225

Target Price

+207.83%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NeuroOne Medical Technologies Corp Highlights

StrengthsRisks

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 62.87% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.45M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.45M.

Undervalued

The company’s latest PE is -4.41, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 16.82M shares, increasing 35.75% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.20M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.35.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.73, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.70M, representing a year-over-year increase of 105.39%, while its net profit experienced a year-over-year increase of 45.77%.

Score

Industry at a Glance

Previous score

6.73

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.35

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.49

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

NeuroOne Medical Technologies Corp's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.08, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -4.41, which is -73.66% below the recent high of -1.16 and -44.85% above the recent low of -6.39.

Score

Industry at a Glance

Previous score

7.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 114/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for NeuroOne Medical Technologies Corp is 2.23, with a high of 3.00 and a low of 1.45.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

2.225

Target Price

+207.83%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

NeuroOne Medical Technologies Corp

NMTC

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.03, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 0.98 and the support level at 0.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.14

Change

-0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.024

Sell

RSI(14)

33.946

Neutral

STOCH(KDJ)(9,3,3)

15.707

Oversold

ATR(14)

0.055

High Vlolatility

CCI(14)

-148.004

Sell

Williams %R

83.263

Oversold

TRIX(12,20)

-0.711

Sell

StochRSI(14)

23.874

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.761

Sell

MA10

0.785

Sell

MA20

0.832

Sell

MA50

0.860

Sell

MA100

0.814

Sell

MA200

0.819

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 33.63%, representing a quarter-over-quarter increase of 26.14%. The largest institutional shareholder is The Vanguard, holding a total of 1.20M shares, representing 2.41% of shares outstanding, with 19.33% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Merchant Adventure Fund LP

4.20M

+236.00%

Bleichroeder LP

4.00M

Sio Capital Management, LLC

3.52M

Manchester Management Company, L.L.C.

2.36M

+57.60%

Bard Associates Inc.

1.85M

Perkins Capital Management, Inc.

1.50M

The Vanguard Group, Inc.

Star Investors

1.20M

+8.27%

AWM Investment Company, Inc.

916.67K

-21.43%

Rosa (David A)

615.75K

-0.40%

Renaissance Technologies LLC

Star Investors

468.90K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.28, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.